source
- Novo claims 80% share of oral GLP-1 market as rivalry with Lilly intensifiesNovo's CEO Mike Maziar Doustdar said the company leads the oral GLP-1 market, stating the Wegovy pill holds about 80% of prescriptions since its launch in January. Eli Lilly, however, reported tha…
- Pfizer targets Europe first for upcoming Lyme disease vaccine amid rising US casesPfizer is planning to launch its Lyme disease vaccine in Europe first, leveraging its existing tick-borne encephalitis franchise in the region. The vaccine, developed with French partner Valneva,…